Today: 20 March 2026
Browse Category

TSX:SRU.UN 15 January 2026 - 12 February 2026

SmartCentres REIT reports 98.6% occupancy in 2025 results as Rezzie rolls out off-market deal marketplace

SmartCentres REIT reports 98.6% occupancy in 2025 results as Rezzie rolls out off-market deal marketplace

SmartCentres REIT reported 98.6% occupancy at year-end 2025 and a 3.7% rise in same-property NOI. Fourth-quarter net rental income and other reached $143.6 million, with FFO at $0.54 per unit. The trust leased 430,000 square feet of vacant space in 2025 and opened three new self-storage facilities. Key agreements with the Penguin group were extended to Feb. 28 as negotiations continue.
12 February 2026
Telus’ 9% dividend yield looks tempting — but CIBC, SmartCentres and Leon’s are the TSX income names in play

Telus’ 9% dividend yield looks tempting — but CIBC, SmartCentres and Leon’s are the TSX income names in play

Telus Corp has paused dividend growth and will maintain its C$0.4184 quarterly payout, while its yield remains near 9% due to a pressured share price. Joey Frenette of Motley Fool Canada flagged CIBC as a more stable alternative, offering a 3.4% yield but facing mortgage risk. SmartCentres REIT yields 6.91%, and Leon’s Furniture, at 3.36%, is considering a REIT spin-off.
15 January 2026

Stock Market Today

  • Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
    March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).
Go toTop